January 14, 2025
Children with asthma scored significantly lower than those without asthma on measures of episodic memory, based on longitudinal data from nearly 500 individuals. Animal models have […]
January 8, 2025
(Reuters) -Eli Lilly’s obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss […]
January 7, 2025
A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is […]
January 7, 2025
TOPLINE: Hospitalized older adults with community-acquired pneumonia (CAP) and sepsis exhibit impaired neutrophil function; however, glycolytic metabolism is not the driver of neutrophil dysfunction. METHODOLOGY: This […]
January 7, 2025
TOPLINE: Nearly one in six adults with asthma in the United States is nonadherent to medications due to costs, with younger patients, women, and those without […]
January 2, 2025
TOPLINE: In a multinational phase 3 trial, imipenem-cilastatin-relebactam demonstrated noninferiority to piperacillin-tazobactam in treating critically ill patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia […]
December 24, 2024
The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in […]
December 23, 2024
When Laura Sadofsky, PhD, a senior lecturer in Respiratory Medicine at the University of Hull, Hull, England, began looking at the effects of microplastic exposure on […]
December 18, 2024
TOPLINE: The presence of cardiovascular comorbidities has minimal effect on the efficacy of inhaled or oral treprostinil when used alongside oral monotherapy in patients with pulmonary […]